SCHEMBL12515157

SCHEMBL12515157

CCc1nc(-c2ccc(NC(=O)c3ccc(OC)cc3C)cc2Cl)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPSE Q9Y251 7/20 0.56
▸ TRPV1 Q8NER1 2/20 0.45
▸ MAPT P10636 3/20 0.45
▸ TP53 P04637 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ PNLIP P16233 1/20 0.42
▸ MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12515154 0.93 HPSE (0.55) HPSEMAPTTP53JAK2TYK2
SCHEMBL12515370 0.92 HPSE (0.54) HPSEMAPTTP53POLBRXFP1
SCHEMBL12515162 0.91 HPSE (0.53) HPSEMAPTTP53LMNAKMT2A
SCHEMBL12515152 0.90 HPSE (0.53) HPSEMAPTTP53POLBJAK2
SCHEMBL12515151 0.89 HPSE (0.69) HPSEMAPTTP53POLBLMNA
SCHEMBL12515823 0.89 NPC1 (0.54) HPSETRPV1MAPTTP53POLB
SCHEMBL12515139 0.86 HPSE (0.49) HPSEMAPTTP53POLBRXFP1
SCHEMBL12515352 0.85 RAB9A (0.58) TRPV1MAPTLMNAGAAALOX12
SCHEMBL12515132 0.85 HPSE (0.47) HPSETRPV1MAPTTP53POLB
SCHEMBL12515146 0.85 HPSE (0.47) HPSETRPV1MAPTTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174949-B2 Hedgehog inhibitors SELEXAGEN THERAPEUTICS, INC. (US) 2015-11-03 — — US disclosed
US-9174949-B2 Hedgehog inhibitors SELEXAGEN THERAPEUTICS, INC. (US) 2015-11-03 — — US disclosed
US-20130012513-A1 HEDGEHOG INHIBITORS SELEXAGEN THERAPEUTICS, INC. 2013-01-10 — — US disclosed
US-20130012513-A1 HEDGEHOG INHIBITORS SELEXAGEN THERAPEUTICS, INC. 2013-01-10 — — US disclosed
WO-2011085128-A1 HEDGEHOG INHIBITORS SELEXAGEN THERAPEUTICS, INC. (US) 2011-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012513-A1 HEDGEHOG INHIBITORS SHH, SMO, GLI1 HPSE 101/4885TRPV1 2108/4885MAPT 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback